文献速递青光眼神经眼科

Meox2单倍剂量不足加速DBA/2J青光眼模型中的轴突变性

Meox2 Haploinsufficiency Accelerates Axonal Degeneration in DBA/2J Glaucoma.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究利用DBA/2J小鼠青光眼模型的转录组数据,通过上游调控因子分析鉴定出Meox2是早期基因表达变化的潜在调控因子;Meox2单倍剂量不足不影响虹膜疾病或眼压升高,但显著增加轴突损伤的眼数,且老年Meox2单倍剂量不足小鼠MEOX2蛋白水平降低44%,与年龄及疾病特异性血管和髓系改变相关。

要点

  • Meox2单倍剂量不足不改变DBA/2J小鼠的虹膜疾病或眼压升高。
  • Meox2单倍剂量不足导致轴突损伤眼数较对照组显著增加。
  • 老年Meox2单倍剂量不足小鼠MEOX2蛋白水平降低44%。

核心结论

  • 数据支持Meox2通过调控眼压依赖性血管重塑和神经炎症促进轴突存活的模型。
  • 在眼压升高前促进这些早期反应可能是延缓或预防人类青光眼的可行神经保护策略。

研究设计与样本

  • 研究对DBA/2J小鼠进行Ingenuity通路分析中的上游调控因子分析,以鉴定差异表达基因的潜在主调控因子。
  • 采用遗传、生化和免疫荧光方法测试了候选调控因子Meox2的功能。

主要发现

  • 上游调控因子分析鉴定出Meox2是DBA/2J小鼠视神经乳头早期基因表达变化的潜在调控因子。
  • Meox2单倍剂量不足不影响DBA/2J小鼠的虹膜特征性疾病或眼压升高,但导致轴突损伤眼数较对照组显著增加。
  • 年轻小鼠表现正常,而老年Meox2单倍剂量不足DBA/2J小鼠MEOX2蛋白水平降低44%。
  • MEOX2蛋白降低与年龄和疾病特异性血管及髓系改变的调节相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glaucoma is a complex disease with major risk factors including advancing age and increased intraocular pressure (IOP). Dissecting these earliest events will likely identify new avenues for therapeutics. Previously, we performed transcriptional profiling in DBA/2J (D2) mice, a widely used mouse model relevant to glaucoma. Here, we use these data to identify and test regulators of early gene expression changes in DBA/2J glaucoma. METHODS: Upstream regulator analysis (URA) in Ingenuity Pathway Analysis was performed to identify potential master regulators of differentially expressed genes. The function of one putative regulator, mesenchyme homeobox 2 (Meox2), was tested using a combination of genetic, biochemical, and immunofluorescence approaches. RESULTS: URA identified Meox2 as a potential regulator of early gene expression changes in the optic nerve head (ONH) of DBA/2J mice. Meox2 haploinsufficiency did not affect the characteristic diseases of the iris or IOP elevation seen in DBA/2J mice but did cause a significant increase in the numbers of eyes with axon damage compared to controls. While young mice appeared normal, aged Meox2 haploinsufficient DBA/2J mice showed a 44% reduction in MEOX2 protein levels. This correlated with modulation of age- and disease-specific vascular and myeloid alterations. CONCLUSIONS: Our data support a model whereby Meox2 controls IOP-dependent vascular remodeling and neuroinflammation to promote axon survival. Promoting these earliest responses prior to IOP elevation may be a viable neuroprotective strategy to delay or prevent human glaucoma.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Buchanan RA, Foley KE, Pepper KW, et al. Meox2 Haploinsufficiency Accelerates Axonal Degeneration in DBA/2J Glaucoma. Invest Ophthalmol Vis Sci. 2019. PMID: 31369031. doi:10.1167/iovs.18-26126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。